502544973 10/24/2013

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT2590482

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MOHAMMAD JAVAD AMAN	10/04/2013
RAJAN PRASAD ADHIKARI	10/04/2013
HATICE KARAUZUM	10/15/2013
KELLY LYN WARFIELD	10/07/2013
TAM LUONG NGUYEN	10/18/2013

RECEIVING PARTY DATA

Name:	INTEGRATED BIOTHERAPEUTICS, INC.
Street Address:	21 FIRSTFIELD ROAD
Internal Address:	SUITE 100
City:	GAITHERSBURG
State/Country:	MARYLAND
Postal Code:	20878

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13984226

CORRESPONDENCE DATA

 Fax Number:
 (202)371-2540

 Phone:
 202-371-2600

Email: bncombs@skgf.com, bswann@skgf.com

Correspondence will be sent via US Mail when the email attempt is unsuccessful.

Correspondent Name: STERNE, KESSLER, GOLDSTEIN & FOX PLLC

Address Line 1: 1100 NEW YORK AVENUE, N.W.

Address Line 4: WASHINGTON, DISTRICT OF COLUMBIA 20005

NAME OF SUBMITTER:	BONNIE W. NANNENGA-COMBS
Signature:	/Bonnie W. Nannenga-Combs #67,836/

502544973 REEL: 031472 FRAME: 0622

340.00 13984226

Date:	10/24/2013
Total Attachments: 2 source=28770050002assignment#page1.tif source=28770050002assignment#page2.tif	

PATENT REEL: 031472 FRAME: 0623

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: Mohammad Javad AMAN, Rajan Prasad ADHIKARI, Hatice KARAUZUM, Kelly Lyn WARFIELD and Tam Luong NGUYEN, hereby sell and assign to Integrated BioTherapeutics, Inc., a corporation formed under the laws of Maryland, whose mailing address is 21 Firstfield Road, Suite 100, Gaithersburg, Maryland 20878 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

- (a) in the invention(s) known as Immunogenic Composition Comprising Alpha-Hemolysin Oligopeptides for which application(s) for patent in the United States of America has a filing date or a 371(c) date of August 8, 2013 (also known as United States Application No. 13/984,226, which is the U.S. national phase of International Application No. PCT/US2012/024031, International Filing Date February 6, 2012), in any and all applications thereon, in any and all Letters Patent(s) therefor, and
- (b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-

PATENT REEL: 031472 FRAME: 0624 part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with CUSTOMER NUMBER 26111 the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with CUSTOMER NUMBER 26111 are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name. M. Javad Aman 2013,10.04 Date: Signature of Inventor: 15:14:17 -04'00' Mohammad Javad AMAN Signature of Inventor: Rajan/Pras MITAD FUN Signature of Inventor: Hatice. Signature of Inventor: Signature of Inventor: 1737265 LDOCX

Page 2 of 2

PATENT REEL: 031472 FRAME: 0625

RECORDED: 10/24/2013